Anti-NMDA receptor encephalitis

Last updated
Anti-NMDA receptor encephalitis
Other namesNMDA receptor antibody encephalitis, anti-N-methyl-D-aspartate receptor encephalitis, anti-NMDAR encephalitis
NR1-NR2B subunit.png
A schematic diagram of the NMDA receptor
Specialty Neurology
Symptoms Early: Fever, headache, feeling tired, psychosis, agitated [1] [2]
Later: Seizures, decreased breathing, blood pressure and heart rate variability [1]
Complications Long term mental or behavioral problems [2]
Usual onsetOver days to weeks [3]
Risk factors Ovarian teratoma, unknown [1] [4]
Diagnostic method Specific antibodies in the cerebrospinal fluid [1]
Differential diagnosis Viral encephalitis, acute psychosis, neuroleptic malignant syndrome [2]
Treatment Immunosuppresive medication, surgery [1]
Medication Corticosteroids, intravenous immunoglobulin (IVIG), plasma exchange, azathioprine [2]
Prognosis Typically good (with treatment) [1]
FrequencyRare [2]
Deaths~4% risk of death [2]

Anti-NMDA receptor encephalitis is a type of brain inflammation caused by antibodies. [4] Early symptoms may include fever, headache, and feeling tired. [1] [2] This is then typically followed by psychosis which presents with false beliefs (delusions) and seeing or hearing things that others do not see or hear (hallucinations). [1] People are also often agitated or confused. [1] Over time, seizures, decreased breathing, and blood pressure and heart rate variability typically occur. [1] In some cases, patients may develop catatonia. [5]

Contents

About half of cases are associated with tumors, most commonly teratomas of the ovaries. [1] [4] Another established trigger is herpesviral encephalitis, while the cause in others cases is unclear. [1] [4] [6] The underlying mechanism is autoimmune, with the primary target being the GluN1 subunit of the N-methyl D-aspartate receptors (NMDAR) in the brain. [1] [7] Diagnosis is typically based on finding specific antibodies in the cerebral spinal fluid. [1] MRI of the brain is often normal. [2] Misdiagnosis is common. [7]

Treatment is typically with immunosuppresive medication and, if a tumor is present, surgery to remove it. [1] With treatment, about 80% of cases have a good outcome. [1] Outcomes are better if treatment is begun earlier. [2] Long-term mental or behavioral problems may remain. [2] About 4% of those affected die from the condition. [2] Recurrence occurs in about 10% of people. [1]

The estimated number of cases of the disease is one in 1.5 million people per year. [8] [6] The condition is relatively common compared to other paraneoplastic disorders. [2] About 80% of those affected are female. [2] It typically occurs in adults younger than 45 years old, but it can occur at any age. [4] [7] The disease was first described by Josep Dalmau in 2007. [1] [9]

Signs and symptoms

Prior to the development of a symptom complex that is specific to anti-NMDA receptor encephalitis, people may experience prodromal symptoms, including headaches, flu-like illness, or symptoms similar to an upper respiratory infection. These symptoms may be present for weeks or months prior to disease onset. [10] Beyond the prodromal symptoms, the disease progresses at varying rates, and patients may present with a variety of neurological symptoms. During the initial stage of the disease, symptoms vary slightly between children and adults. However, behavior changes are a common first symptom within both groups. These changes often include agitation, paranoia, psychosis, and violent behaviors. [11] Other common manifestations include seizures and bizarre movements, mostly of the lips and mouth, but also including pedaling motions with the legs or hand movements resembling playing a piano [ citation needed ]. Some other symptoms typical during the disease onset include impaired cognition, memory deficits, and speech problems (including aphasia, perseveration or mutism). [12] [13]

The symptoms usually appear psychiatric in nature, which may confound the differential diagnosis. In many cases, this leads to the illness going undiagnosed. [14] As the disease progresses, the symptoms become medically urgent and often include autonomic dysfunction, hypoventilation, cerebellar ataxia, loss of feeling on one side of the body, [15] loss of consciousness, or catatonia. [16] During this acute phase, most patients require treatment in an intensive care unit to stabilize breathing, heart rate, and blood pressure.[ citation needed ] One distinguishing characteristic of anti-NMDA receptor encephalitis is the concurrent presence of many of the above listed symptoms. The majority of patients experience at least four symptoms, with many experiencing six or seven over the course of the disease. [12] [13]

Pathophysiology

The condition is mediated by autoantibodies that target NMDA receptors in the brain. [17] These can be produced by cross reactivity with NMDA receptors in teratomas, which contain many cell types, including brain cells, and thus present a window in which a breakdown in immunological tolerance can occur. Other autoimmune mechanisms are suspected for patients who do not have tumors. Whilst the exact pathophysiology of the disease is still debated, empirical evaluation of the origin of anti-NMDA receptor antibodies in serum and cerebrospinal fluid leads to the consideration of two possible mechanisms.[ citation needed ]

These mechanisms may be informed by some simple observations. Serum NMDA receptor antibodies are consistently found at higher concentrations than cerebrospinal fluid antibodies, on average ten times higher. [18] [19] This strongly suggests the antibody production is systemic rather than in the brain or cerebrospinal fluid. When concentrations are normalized for total IgG, intrathecal synthesis is detected. This implies that there are more NMDA receptor antibodies in the cerebrospinal fluid than would be predicted given the expected quantities of total IgG.[ citation needed ]

  1. Passive access involves the diffusion of antibodies from the blood across a pathologically disrupted blood-brain barrier (BBB). [20] This cellular filter, separating the central nervous system from the circulatory system, normally prevents larger molecules from entering the brain. A variety of reasons for such a collapse in integrity have been suggested, with the most likely answer being the effects of acute inflammation of the nervous system. Likewise, the involvement of corticotropin releasing hormone on mast cells in acute stress has been shown to facilitate BBB penetration. [21] However, it is also possible that the autonomic dysfunction manifested in many patients during the later phases of the condition aids antibody entry. For example, an increase in blood pressure would force larger proteins, such as antibodies, to extravasate into the cerebrospinal fluid.
  2. Intrathecal production (production of antibodies in the intrathecal space) is also a possible mechanism. [22] Dalmau et al. demonstrated that 53 out of 58 patients with the condition had at least partially preserved BBBs, whilst having a high concentration of antibodies in the cerebrospinal fluid. Furthermore, cyclophosphamide and rituximab, drugs used to eliminate dysfunctional immune cells, have been shown to be successful second-line treatments in patients where first-line immunotherapy has failed. [23] These destroy excess antibody-producing cells in the thecal sac, thus alleviating the symptoms.

A more sophisticated analysis of the processes involved in antibody presence in the cerebrospinal fluid hints at a combination of these two mechanisms in tandem.[ citation needed ]

Antibodies

Once the antibodies have entered the CSF, they bind to the NR1 subunit of the NMDA receptor. There are three possible methods in which neuronal damage occurs.

  1. A reduction in the density of NMDA receptors on the post synaptic knob, due to receptor internalization once the antibody has bound. This is dependent on antibodies cross linking. [24]
  2. The direct antagonism of the NMDA receptor by the antibody, similar to the action of the classic dissociative anesthetics phencyclidine and ketamine.
  3. The recruitment of the complement cascade via the classical pathway (antibody-antigen interaction). Membrane attack complex (MAC) is one of the end products of this cascade [25] and can insert into neurons as a molecular barrel, allowing water to enter. The cell subsequently lyses. Notably, this mechanism is unlikely as it causes the cell to die, which is inconsistent with current evidence.

Diagnosis

First and foremost is a high level of clinical suspicion, especially in young adults showing abnormal behavior as well as autonomic instability. Clinical examination may further reveal delusions and hallucinations, which can aid diagnostic efforts.[ citation needed ]

The initial investigation usually consists of clinical examination, MRI of the brain, an EEG, and a lumbar puncture for CSF analysis. MRI of the brain may show abnormalities in the temporal and frontal lobes, but do so in less than half of cases. A FDG-PET scan of the brain may show abnormalities in cases when the MRI scan is normal. [26] EEG is abnormal in almost 90% of cases and typically shows general or focal slow wave activity. [27] CSF analysis often shows inflammatory changes with increased levels of white blood cells, total protein and the presence of oligoclonal bands. [28] NMDA receptor antibodies can be detected in serum and/or CSF. Whole body FDG-PET is usually performed as a part of tumor screening. Gynecological ultrasound or a pelvic MRI might be performed to search for an ovarian teratoma in women.

Diagnostic criteria for probable and definite anti-NMDA receptor encephalitis have been proposed to facilitate diagnosis at an early stage of the disease and help initiate early treatment. [29]

Management

If a person is found to have a tumor, the long-term prognosis is generally better and the chance of relapse is much lower. This is because the tumor can be removed surgically, thus eradicating the source of autoantibodies. In general, early diagnosis and aggressive treatment is believed to improve patient outcomes, but this remains impossible to know without data from randomized controlled trials. [12] Given that the majority of patients are initially seen by psychiatrists, it is critical that all physicians (especially psychiatrists) consider anti-NMDA receptor encephalitis as a possible cause of acute psychosis in young patients with no past neuropsychiatric history.[ citation needed ]

Prognosis

The recovery process from anti-NMDAR encephalitis can take many months. The symptoms may reappear in reverse order: The patient may begin to experience psychosis again, leading many people to falsely believe the patient is not recovering. As the recovery process continues on, the psychosis fades. Lastly, the person's social behavior and executive functions begin to improve. [10]

Epidemiology

The estimated number of cases of the disease is 1.5 per million people per year. [6] According to the California Encephalitis Project, the disease has a higher incidence than its individual viral counterparts in patients younger than 30. [31] The largest case series as of 2013 characterized 577 people with anti-NMDA receptor encephalitis. The data were limited, but provides the best approximation of disease distribution. It found that women make up 81% of cases. Disease onset is skewed toward children, with a median age of diagnosis of 21 years. Over a third of cases were children, while only 5% of cases were patients over the age of 45. This same review found that 394 out of 501 patients (79%) had a good outcome by 24 months. [12] 30 people (6%) died, and the rest were left with mild to severe deficits. The study mentioned that of the 38% presenting with tumors, 94% of those presented with ovarian teratomas. Within that subset, African & Asian women were more likely to have a tumor, but this was not relevant to the prevalence of the disease within those racial groups. [12]

Society and culture

Anti-NMDA receptor encephalitis is suspected of being an underlying cause of historical accounts of demonic possession. [32] [33] [34] [35]

New York Post reporter Susannah Cahalan wrote a book titled Brain on Fire: My Month of Madness about her experience with the disease. [33] This has subsequently been turned into a film of the same name. [36]

Dallas Cowboys defensive lineman Amobi Okoye spent 17 months battling anti-NMDA receptor encephalitis. In addition to three months in a medically-induced coma, he experienced a 145-day memory gap and lost 78 pounds. He returned to practice on October 23, 2014. [37]

In the Japanese movie called The 8-Year Engagement , a young Japanese woman ends up being in a coma due to anti-NMDA receptor encephalitis.

Knut, a polar bear at the Berlin Zoological Garden that died on 19 March 2011, was diagnosed with anti-NMDA receptor encephalitis in August 2015. This was the first case discovered in a non-human animal. [38] [39] [40]

In Hannibal , Will Graham was affected by NMDA receptor or antibody encephalitis, also known as anti-NMDAR encephalitis. [41]

The TV series Something's Killing Me featured an episode called "Into Madness" that featured two cases of the disease. [42]

Figures

An extreme delta brush in a patient. This EEG pattern is sometimes observed in anti-NMDAr encephalitis. From Mizoguchi et al., 2022. Extreme delta brush in anti-NMDAr encephalitis.png
An extreme delta brush in a patient. This EEG pattern is sometimes observed in anti-NMDAr encephalitis. From Mizoguchi et al., 2022.

See also

Related Research Articles

<span class="mw-page-title-main">Encephalitis</span> Inflammation of the brain

Encephalitis is inflammation of the brain. The severity can be variable with symptoms including reduction or alteration in consciousness, headache, fever, confusion, a stiff neck, and vomiting. Complications may include seizures, hallucinations, trouble speaking, memory problems, and problems with hearing.

Serine is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group, a carboxyl group, and a side chain consisting of a hydroxymethyl group, classifying it as a polar amino acid. It can be synthesized in the human body under normal physiological circumstances, making it a nonessential amino acid. It is encoded by the codons UCU, UCC, UCA, UCG, AGU and AGC.

<span class="mw-page-title-main">NMDA receptor</span> Glutamate receptor and ion channel protein found in nerve cells

The N-methyl-D-aspartatereceptor (also known as the NMDA receptor or NMDAR), is a glutamate receptor and ion channel found in neurons. The NMDA receptor is one of three types of ionotropic glutamate receptors, the other two being AMPA and kainate receptors. Depending on its subunit composition, its ligands are glutamate and glycine (or D-serine). However, the binding of the ligands is typically not sufficient to open the channel as it may be blocked by Mg2+ ions which are only removed when the neuron is sufficiently depolarized. Thus, the channel acts as a “coincidence detector” and only once both of these conditions are met, the channel opens and it allows positively charged ions (cations) to flow through the cell membrane. The NMDA receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions.

Neuromyelitis optica spectrum disorders (NMOSD), including neuromyelitis optica (NMO), are autoimmune diseases characterized by acute inflammation of the optic nerve and the spinal cord (myelitis). Episodes of ON and myelitis can be simultaneous or successive. A relapsing disease course is common, especially in untreated patients. In more than 80% of cases, NMO is caused by immunoglobulin G autoantibodies to aquaporin 4 (anti-AQP4), the most abundant water channel protein in the central nervous system. A subset of anti-AQP4-negative cases is associated with antibodies against myelin oligodendrocyte glycoprotein (anti-MOG). Rarely, NMO may occur in the context of other autoimmune diseases or infectious diseases. In some cases, the etiology remains unknown.

Rasmussen's encephalitis is a rare inflammatory neurological disease, characterized by frequent and severe seizures, loss of motor skills and speech, hemiparesis, encephalitis, and dementia. The illness affects a single cerebral hemisphere and generally occurs in children under the age of 15.

<span class="mw-page-title-main">Glutamate receptor</span> Cell-surface proteins that bind glutamate and trigger changes which influence the behavior of cells

Glutamate receptors are synaptic and non synaptic receptors located primarily on the membranes of neuronal and glial cells. Glutamate is abundant in the human body, but particularly in the nervous system and especially prominent in the human brain where it is the body's most prominent neurotransmitter, the brain's main excitatory neurotransmitter, and also the precursor for GABA, the brain's main inhibitory neurotransmitter. Glutamate receptors are responsible for the glutamate-mediated postsynaptic excitation of neural cells, and are important for neural communication, memory formation, learning, and regulation.

Experimental autoimmune encephalomyelitis, sometimes experimental allergic encephalomyelitis (EAE), is an animal model of brain inflammation. It is an inflammatory demyelinating disease of the central nervous system (CNS). It is mostly used with rodents and is widely studied as an animal model of the human CNS demyelinating diseases, including multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM). EAE is also the prototype for T-cell-mediated autoimmune disease in general.

<span class="mw-page-title-main">Meningoencephalitis</span> Medical condition

Meningoencephalitis, also known as herpes meningoencephalitis, is a medical condition that simultaneously resembles both meningitis, which is an infection or inflammation of the meninges, and encephalitis, which is an infection or inflammation of the brain tissue.

Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) due to the unknown etiology of some of them, are a heterogenous group of demyelinating diseases - conditions that cause damage to myelin, the protective sheath of nerve fibers - that occur against the background of an acute or chronic inflammatory process. IDDs share characteristics with and are often grouped together under Multiple Sclerosis. They are sometimes considered different diseases from Multiple Sclerosis, but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.

<span class="mw-page-title-main">Hashimoto's encephalopathy</span> Human disease (neurological condition)

Hashimoto's encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is a neurological condition characterized by encephalopathy, thyroid autoimmunity, and good clinical response to corticosteroids. It is associated with Hashimoto's thyroiditis, and was first described in 1966. It is sometimes referred to as a neuroendocrine disorder, although the condition's relationship to the endocrine system is widely disputed. It is recognized as a rare disease by the NIH Genetic and Rare Diseases Information Center.

<span class="mw-page-title-main">Limbic encephalitis</span> Inflammation involving the limbic system in the brain

Limbic encephalitis is a form of encephalitis, a disease characterized by inflammation of the brain. Limbic encephalitis is caused by autoimmunity: an abnormal state where the body produces antibodies against itself. Some cases are associated with cancer and some are not. Although the disease is known as "limbic" encephalitis, it is seldom limited to the limbic system and post-mortem studies usually show involvement of other parts of the brain. The disease was first described by Brierley and others in 1960 as a series of three cases. The link to cancer was first noted in 1968 and confirmed by later investigators.

A paraneoplastic syndrome is a syndrome that is the consequence of a tumor in the body. It is specifically due to the production of chemical signaling molecules by tumor cells or by an immune response against the tumor. Unlike a mass effect, it is not due to the local presence of cancer cells.

Anti-glutamate receptor antibodies are autoantibodies detected in serum and/or cerebrospinal fluid samples of a variety of disorders such as encephalitis, epilepsy and ataxia. Clinical and experimental studies starting around the year 2000 suggest that these antibodies are not simply epiphenomena and are involved in autoimmune disease pathogenesis.

<span class="mw-page-title-main">Herpes simplex encephalitis</span> Encephalitis associated with herpes simplex virus

Herpes simplex encephalitis (HSE), or simply herpes encephalitis, is encephalitis due to herpes simplex virus. It is estimated to affect at least 1 in 500,000 individuals per year, and some studies suggest an incidence rate of 5.9 cases per 100,000 live births.

Bickerstaff brainstem encephalitis is a rare inflammatory disorder of the central nervous system, first described by Edwin Bickerstaff in 1951. It may also affect the peripheral nervous system, and has features in common with both Miller Fisher syndrome and Guillain–Barré syndrome.

<span class="mw-page-title-main">Lymphocytic pleocytosis</span> Increase in lymphocytes within cerebrospinal fluid

Lymphocytic pleocytosis is an abnormal increase in the amount of lymphocytes in the cerebrospinal fluid (CSF). It is usually considered to be a sign of infection or inflammation within the nervous system, and is encountered in a number of neurological diseases, such as pseudomigraine, Susac's syndrome, and encephalitis. While lymphocytes make up roughly a quarter of all white blood cells (WBC) in the body, they are generally rare in the CSF. Under normal conditions, there are usually less than 5 white blood cells per µL of CSF. In a pleocytic setting, the number of lymphocytes can jump to more than 1,000 cells per µL. Increases in lymphocyte count are often accompanied by an increase in cerebrospinal protein concentrations in addition to pleocytosis of other types of white blood cells.

<span class="mw-page-title-main">Autoimmune encephalitis</span> Type of encephalitis

Autoimmune encephalitis (AIE) is a type of encephalitis, and one of the most common causes of noninfectious encephalitis. It can be triggered by tumors, infections, or it may be cryptogenic. The neurological manifestations can be either acute or subacute and usually develop within six weeks. The clinical manifestations include behavioral and psychiatric symptoms, autonomic disturbances, movement disorders, and seizures.

Anti-VGKC-complex encephalitis are caused by antibodies against the voltage gated potassium channel-complex (VGKC-complex) and are implicated in several autoimmune conditions including limbic encephalitis, epilepsy and neuromyotonia.

Anti-Hu associated encephalitis, also known as Anti-ANNA1 associated encephalitis, is an uncommon form of brain inflammation that is associated with an underlying cancer. It can cause psychiatric symptoms such as depression, anxiety, and hallucinations. It can also produce neurological symptoms such as confusion, memory loss, weakness, sensory loss, pain, seizures, and problems coordinating the movement of the body.

Anti-IgLON5 disease is a neurodegenerative autoimmune disease. It is marked by parasomnias and chorea - an involuntary movement disorder.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Kayser MS, Dalmau J (September 2016). "Anti-NMDA receptor encephalitis, autoimmunity, and psychosis". Schizophrenia Research. 176 (1): 36–40. doi:10.1016/j.schres.2014.10.007. PMC   4409922 . PMID   25458857.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 Kayser MS, Dalmau J (2011). "Anti-NMDA Receptor Encephalitis in Psychiatry". Current Psychiatry Reviews. 7 (3): 189–193. doi:10.2174/157340011797183184. PMC   3983958 . PMID   24729779.
  3. ↑ Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE (2013). Abeloff's Clinical Oncology E-Book. Elsevier Health Sciences. p. 600. ISBN   9781455728817.
  4. 1 2 3 4 5 Venkatesan A, Adatia K (December 2017). "Anti-NMDA-Receptor Encephalitis: From Bench to Clinic". ACS Chemical Neuroscience. 8 (12): 2586–2595. doi:10.1021/acschemneuro.7b00319. PMID   29077387.
  5. ↑ Wu H, Wu C, Zhou Y, Huang S, Zhu S (February 2023). "Catatonia in adult anti-NMDAR encephalitis: an observational cohort study". BMC Psychiatry. 23 (1): 94. doi: 10.1186/s12888-022-04505-x . PMC   9903498 . PMID   36750806.
  6. 1 2 3 Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, et al. (November 2019). "An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models". The Lancet. Neurology. 18 (11): 1045–1057. doi:10.1016/S1474-4422(19)30244-3. PMID   31326280. S2CID   197464804.
  7. 1 2 3 Minagar A, Alexander JS (2017). Inflammatory Disorders of the Nervous System: Pathogenesis, Immunology, and Clinical Management. Humana Press. p. 177. ISBN   9783319512204 . Retrieved 14 July 2018.
  8. ↑ Samanta D, Lui F (2022). "Anti-NMDA Receptor Encephalitis". StatPearls. StatPearls. PMID   31869136.
  9. ↑ Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. (January 2007). "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma". Annals of Neurology. 61 (1): 25–36. doi:10.1002/ana.21050. PMC   2430743 . PMID   17262855.
  10. 1 2 Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. (December 2008). "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies". The Lancet. Neurology. 7 (12): 1091–1098. doi:10.1016/S1474-4422(08)70224-2. PMC   2607118 . PMID   18851928.
  11. ↑ Agarwal R, Gupta V (2022). "Anti-NMDA Receptor Encephalitis In Children". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32965889 . Retrieved 2023-02-24.
  12. 1 2 3 4 5 6 Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. (February 2013). "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study". The Lancet. Neurology. 12 (2): 157–165. doi:10.1016/S1474-4422(12)70310-1. PMC   3563251 . PMID   23290630.
  13. 1 2 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (January 2011). "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis". The Lancet. Neurology. 10 (1): 63–74. doi:10.1016/s1474-4422(10)70253-2. PMC   3158385 . PMID   21163445.
  14. ↑ Greiner H, Leach JL, Lee KH, Krueger DA (April 2011). "Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome". Seizure. 20 (3): 266–270. doi: 10.1016/j.seizure.2010.11.013 . PMID   21146427. S2CID   5839321.
  15. ↑ Cahalan S (2013). Brain on Fire-My Month of Madness. New York: Simon & Schuster.
  16. ↑ Eyre M, Kaushik A, Barrett E, King MD, Pollak T, Dale RC, et al. (2020). "Catatonic features in children and adolescents with N-methyl-d-aspartate receptor antibody encephalitis". BJPsych Open. 6 (4): e71. doi:10.1192/bjo.2020.55. ISSN   2056-4724. PMC   7443916 .
  17. ↑ Li Y, Yang K, Zhang F, Wang J, Shen H, Liu M, et al. (2022). "Identification of cerebrospinal fluid biomarker candidates for anti-N-methyl-D-aspartate receptor encephalitis: High-throughput proteomic investigation". Frontiers in Immunology. 13: 971659. doi: 10.3389/fimmu.2022.971659 . PMC   9643472 . PMID   36389787.
  18. ↑ Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. (June 2010). "N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes". Brain. 133 (Pt 6): 1655–1667. doi:10.1093/brain/awq113. PMC   2877907 . PMID   20511282.
  19. ↑ Suh-Lailam BB, Haven TR, Copple SS, Knapp D, Jaskowski TD, Tebo AE (June 2013). "Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay". Clinica Chimica Acta; International Journal of Clinical Chemistry. 421: 1–6. doi:10.1016/j.cca.2013.02.010. PMID   23454475.
  20. ↑ Moscato EH, Jain A, Peng X, Hughes EG, Dalmau J, Balice-Gordon RJ (July 2010). "Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies". The European Journal of Neuroscience. 32 (2): 298–309. doi:10.1111/j.1460-9568.2010.07349.x. PMC   2955837 . PMID   20646055.
  21. ↑ Rabchevsky AG, Degos JD, Dreyfus PA (June 1999). "Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis". Brain Research. 832 (1–2): 84–96. doi:10.1016/S0006-8993(99)01479-1. PMID   10375654. S2CID   27036707.
  22. ↑ Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, et al. (November 2017). "NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody". Annals of Clinical and Translational Neurology. 4 (11): 768–783. doi:10.1002/acn3.444. PMC   5682115 . PMID   29159189.
  23. ↑ Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. (July 2009). "Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents". Annals of Neurology. 66 (1): 11–18. doi:10.1002/ana.21756. PMC   2826225 . PMID   19670433.
  24. ↑ Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. (April 2010). "Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis". The Journal of Neuroscience. 30 (17): 5866–5875. doi:10.1523/JNEUROSCI.0167-10.2010. PMC   2868315 . PMID   20427647.
  25. ↑ Abbas AK, Lichtman AH, Pillai S (2011). Cellular and Molecular Immunology (7th ed.). Elsevier Health Sciences. ISBN   978-1-4377-3573-4.
  26. ↑ Bacchi S, Franke K, Wewegama D, Needham E, Patel S, Menon D (June 2018). "Magnetic resonance imaging and positron emission tomography in anti-NMDA receptor encephalitis: A systematic review". Journal of Clinical Neuroscience. 52: 54–59. doi:10.1016/j.jocn.2018.03.026. PMID   29605275. S2CID   4565748.
  27. ↑ Gillinder L, Warren N, Hartel G, Dionisio S, O'Gorman C (February 2019). "EEG findings in NMDA encephalitis - A systematic review". Seizure. 65: 20–24. doi: 10.1016/j.seizure.2018.12.015 . PMID   30597400.
  28. ↑ Blinder T, Lewerenz J (2019-07-25). "Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis". Frontiers in Neurology. 10: 804. doi: 10.3389/fneur.2019.00804 . PMC   6670288 . PMID   31404257.
  29. ↑ Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. (April 2016). "A clinical approach to diagnosis of autoimmune encephalitis". The Lancet. Neurology. 15 (4): 391–404. doi:10.1016/s1474-4422(15)00401-9. PMC   5066574 . PMID   26906964.
  30. ↑ Liba Z, Sebronova V, Komarek V, Sediva A, Sedlacek P (May 2013). "Prevalence and treatment of anti-NMDA receptor encephalitis". The Lancet. Neurology. 12 (5): 424–425. doi: 10.1016/S1474-4422(13)70070-X . PMID   23602156. S2CID   31746114.
  31. ↑ Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (April 2012). "The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project". Clinical Infectious Diseases. 54 (7): 899–904. doi:10.1093/cid/cir1038. PMC   3297648 . PMID   22281844.
  32. ↑ Lamas DJ (27 May 2013). "When the brain is under attack". The Boston Globe .
  33. 1 2 "A YoungReporter Chronicles Her 'Brain On Fire'". Fresh Air. WHYY; NPR. November 14, 2012. Retrieved September 20, 2013.
  34. ↑ Tam J, Zandi MS (July 2017). "The witchcraft of encephalitis in Salem". Journal of Neurology. 264 (7): 1529–1531. doi:10.1007/s00415-017-8546-4. PMID   28631128. S2CID   36151332.
  35. ↑ Sébire G (January 2010). "In search of lost time from "Demonic Possession" to anti-N-methyl-D-aspartate receptor encephalitis". Annals of Neurology. 67 (1): 141–142. doi:10.1002/ana.21928. PMID   20186949. S2CID   2366741.
  36. ↑ Hornaday A, O'Sullivan M. "What to watch with your kids: 'Ant-Man and the Wasp,' 'Leave No Trace' and more". Washington Post. Retrieved 14 July 2018.
  37. ↑ Whitmire K (2014-10-23). "Cowboys' Okoye returns to practice after battling rare brain disease". www.foxsports.com. FOX Sports Southwest. Retrieved 24 October 2014.
  38. ↑ Nuwer R (27 August 2015). "Knut the Polar Bear's Mysterious Death Finally Solved". Smithsonian.
  39. ↑ Armitage H (27 August 2015). "Death of beloved polar bear, Knut, solved". Science. doi:10.1126/science.aad1675.
  40. ↑ Prüss H, Leubner J, Wenke NK, Czirják GÁ, Szentiks CA, Greenwood AD (August 2015). "Anti-NMDA Receptor Encephalitis in the Polar Bear (Ursus maritimus) Knut". Scientific Reports. 5 (12805): 12805. Bibcode:2015NatSR...512805P. doi:10.1038/srep12805. PMC   4551079 . PMID   26313569.
  41. ↑ Pitt A (21 February 2018). "Hannibal and Anti-NMDAR Encephalitis". Encephalitis Society. North Yorkshire.
  42. ↑ "Something's Killing Me Season 1".[ permanent dead link ]
  43. ↑ Mizoguchi T, Hara M, Hirose S, Nakajima H (2022). "Novel qEEG Biomarker to Distinguish Anti-NMDAR Encephalitis From Other Types of Autoimmune Encephalitis". Frontiers in Immunology. 13: 845272. doi: 10.3389/fimmu.2022.845272 . PMC   8885512 . PMID   35242143.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.